Frezent is a therapeutics startup developing complex biologics, including antibody-drug conjugates (ADCs) and bispecific antibodies, aimed at treating minimal residual disease in cancer therapy. Our focus is on targeting dormant cancer cells that survive chemotherapy and can potentially lead to cancer recurrence. What sets our technology apart is its ability to eliminate non-dividing cancer cells, which is crucial for preventing relapse. If successful, our approach could revolutionize cancer treatment by addressing two key shortcomings of current therapies. First, most existing treatments are effective only on dividing cells, and second, conventional chemotherapy and radiotherapy often contribute to the formation of dormant cancer cells. Our biologics have the potential to eliminate these residual cells and prevent minimal residual disease from progressing into aggressive, recurrent cancer.

Frezent is currently in the preclinical stage, conducting studies in animal models to validate our promising initial data. We are actively raising funding to support lead antibody optimization and in vivo validation.

Please feel free to reach out if you’d like to discuss our technology, explore potential collaboration, or consider investment opportunities. You can use my Calendly link to select time for a meeting:
https://calendly.com/frezent-natasha/schedule-a-meeting